EFMC-ASMC'19

EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry

 Athens, Greece    September 1-5, 2019

Opening Lecture

Opening Lecture
The Art and Science of Total Synthesis and its Impact on Biology and Medicine: From the Fundamentals to the Translational (T01)

Prof. K.C. NICOLAOU
Prof. K.C. NICOLAOU
RICE UNIVERSITY, Houston, United States
Read more

Invited Speakers

Flow Chemistry and Photochemistry as a Tool for Drug Discovery (T23)

Dr Jesus ALCAZAR
Dr Jesus ALCAZAR
JANSSEN RESEARCH & DEVELOPMENT, Toledo, Spain
Read more

Awareness of PAINS (Pan Assay Interference Compounds) can Accelerate the Drug Discovery Process (T14)

Prof. Jonathan BAELL
Prof. Jonathan BAELL
MONASH UNIVERSITY, Parkville, Australia
Read more

Artificial Intelligence in ADMET Modeling and Compound Profiling (T15)

Dr Karl-Heinz BARINGHAUS
Dr Karl-Heinz BARINGHAUS
SANOFI, Frankfurt, Germany
Read more

TLR7/8 Antagonists: from Screening to in vivo Potency (T26)

Dr Claudia BETSCHART
Dr Claudia BETSCHART
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

RNA Therapeutics: New Chemical Modalities Becoming a Therapeutic Reality (T25)

Dr Konrad BLEICHER
Dr Konrad BLEICHER
F.HOFFMANN-LA ROCHE LTD, Basel, Switzerland
Read more

Sustainable by Design Anti-Trypanosomatid Small Molecules: an Aspirational Goal for Medicinal Chemistry (T16) - ChemMedChem Lecture

Prof. Maria Laura BOLOGNESI
Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Read more

Catalytic Chirality Generation: New Strategies for Organic Synthesis (T06)

Prof. John BOWER
Prof. John BOWER
UNIVERSITY OF BRISTOL, Bristol, United Kingdom
Read more

Nature’s Medicine Chest: Opportunities for Synthesis and Drug Discovery (T02)

Prof. Margaret Anne BRIMBLE
Prof. Margaret Anne BRIMBLE
THE UNIVERSITY OF AUCKLAND, Auckland, New Zealand
Read more

Allosteric Activation of a Master Metabolic Regulator AMPK: Drug Discovery Opportunities and Challenges (T27)

Dr Kimberly CAMERON
Dr Kimberly CAMERON
PFIZER, Cambridge, United States
Read more

Design and Synthesis of Chemical Probes for Bromodomains (T10)

Prof. Stuart CONWAY
Prof. Stuart CONWAY
UNIVERSITY OF OXFORD, Los Angeles, United States
Read more

Start Selective and Rigidify: The Discovery Path Towards the Next Generation of EGFR Tyrosine Kinase Inhibitors (T24)

Dr Harald ENGELHARDT
Dr Harald ENGELHARDT
BOEHRINGER-INGELHEIM, Vienna, Austria
Read more

Artificial Intelligence in de Novo Molecular Design (T17)

Dr Ola ENGKVIST
Dr Ola ENGKVIST
ASTRAZENECA, Mölndal, Sweden
Read more

Design and Implementation of de Novo Biosynthetic Cascades (T20)

Prof. Sabine FLITSCH
Prof. Sabine FLITSCH
UNIVERSITY OF MANCHESTER, Manchester, United Kingdom
Read more

Catalysis for Total Synthesis (T21)

Prof. Alois FÜRSTNER
Prof. Alois FÜRSTNER
MAX PLANCK INSTITUT FUR KOHLENFORSCHUNG, Muelheim an der Ruhr, Germany
Read more

Amides and Chemical Education as Vehicles for Innovation (T18)

Prof. Neil GARG
Prof. Neil GARG
UNIVERSITY OF CALIFORNIA, Los Angeles, United States
Read more

A Chemical Approach to Map Protein Interactions at the Cell Surface (T12)

Dr Erik HETT
Dr Erik HETT
MERCK EXPLORATORY SCIENCE CENTER, Boston, United States
Read more

A Medicinal Chemist's Perspective on Solute Carriers: Avoiding or Targeting them (T11)

Dr Kim HUARD
Dr Kim HUARD
GENENTECH, San Francisco, United States
Read more

Practical Heteroatom- and Group-Transfer Reactions (T09)

Dr Laszlo KURTI
Dr Laszlo KURTI
RICE UNIVERSITY, Houston, United States
Read more

Discovery of AZD5718, a Novel 5-lipoxygenase Activating Protein (FLAP) Inhibitor (T19)

Dr Malin LEMURELL
Dr Malin LEMURELL
ASTRAZENECA, Gothenburg, Sweden
Read more

Photoinduced Assembly of C–N Bonds (T08)

Prof. Daniele LEONORI
Prof. Daniele LEONORI
UNIVERSITY OF MANCHESTER, Aachen, Germany
Read more

Discovery of First in Class, Orally Bioavailable p300/CBP HAT Domain Inhibitors (T04)

Dr Michael MICHAELIDES
Dr Michael MICHAELIDES
ABBVIE, North Chicago, United States
Read more

Drug Discovery in Academia (T03)

Prof. Oliver PLETTENBURG
Prof. Oliver PLETTENBURG
LEIBNIZ UNIVERSITY HANNOVER, Hannover, Germany
Read more

From Fragments to Antibody Drug Conjugates in Emerging Oncology Targeted Therapies (T13)

Dr Laurent SCHIO
Dr Laurent SCHIO
SANOFI, Vitry sur Seine, France
Read more

Nucleophilic Boron for the Synthesis of Functionalized Small Rings (T07)

Prof. Mariola TORTOSA
Prof. Mariola TORTOSA
AUTONOMOUS UNIVERSITY OF MADRID, Madrid, Spain
Read more

Development and Application in Flow of Sustainable Synthetic Methodologies that Use Singlet Oxygen as Green Oxidant and Cascade Reaction Facilitator (T22)

Prof. Georgios VASSILIKOGIANNAKIS
Prof. Georgios VASSILIKOGIANNAKIS
UNIVERSITY OF CRETE, Heraklion, Greece
Read more

Novel Bacterial Topoisomerase Inhibitors (NBTI) with Potent Gram-Negative Activity (T05)

Dr Cornelia ZUMBRUNN
Dr Cornelia ZUMBRUNN
IDORSIA PHARMACEUTICALS, Allschwil, Switzerland
Read more

Oral Communications

Rapid Exploration of Synthetically Tractable Chemical Space and Lead Optimization Using a Combination of Reaction-Based Enumeration, Active Learning, and Free Energy Calculations (OC02)

Dr Tatjana BRAUN
Dr Tatjana BRAUN
SCHRÖDINGER, Mannheim, Germany
Read more

Developing a ‘Reverse-Biomimetic’ Synthesis of Arogenate and its Analogues (OC09)

Ms Louise EAGLING
Ms Louise EAGLING
UNIVERSITY OF BRISTOL, Bristol, United Kingdom
Read more

Macrocyclic Modalities for Modulation of Protein-Protein Interactions (OC06)

Dr Stéphanie GUERET
Dr Stéphanie GUERET
ASTRAZENECA MPI SATELLITE UNIT, Mölndal, Sweden
Read more

EFMC Prize for a Young Medicinal Chemist in Academia
From the Elucidation of the Mechanism of Vitamin E to the Design of Innovative Drugs that Limit Inflammation and Enhance Resolution (OC10)

Dr Andreas KOEBERLE
Dr Andreas KOEBERLE
UNIVERSITY OF JENA, Jena, Germany
Read more

Stabilizing Inactive Conformations of MALT1 AS an Effective Strategy to Inhibit its Protease Activity (OC05)

Dr Jean-Baptiste LANGLOIS
Dr Jean-Baptiste LANGLOIS
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

EFMC Prize Winner EFMC-YMCS 2018
Development of Release-And-Report Kinase Inhibitors as Molecular Tools for Investigating Neurodegenerative Disorders (OC04)

Dr Cassandra LEE FLEMING
Dr Cassandra LEE FLEMING
UNIVERSITY OF GOTHENBURG, Gothenburg, Sweden
Read more

A Radical Approach for the Late-Stage Functionalization of Phosphinic Peptides (OC03)

Mr Angelos LELIS
Mr Angelos LELIS
UNIVERSITY OF ATHENS, Athens, Greece

Practical and Asymmetric Gilman-Speeter Synthesis of B-Lactams (OC01)

Prof. Plato MAGRIOTIS
Prof. Plato MAGRIOTIS
UNIVERSITY OF PATRAS, Patras, Greece
Read more

Discovery of GSK701, a Novel Orally Effective Preclinical Drug Candidate for the Treatment of Malaria (OC08)

Dr Jose Ignacio MARTIN
Dr Jose Ignacio MARTIN
GSK, Tres Cantos, Spain
Read more

Removable Directing Groups for Late-Stage Functionalisation (OC12)

Dr Miriam O'DUILL
Dr Miriam O'DUILL
NATIONAL UNIVERSITY OF IRELAND, Galway, Ireland
Read more

Antimicrobial Activity of Curcumin Analog PGV-6, HGV-6 and GVT-6 (OC07)

Prof. Leni RITMALENI
Prof. Leni RITMALENI
GADJAH MADA UNIVERSITY, Yogyakarta, Indonesia
Read more

EFMC Prize for a Young Medicinal Chemist in Industry
Cipargamin-Biocatalysis in the Discovery and Development of an Antimalarial Drug (OC11)

Dr Radka SNAJDROVA
Dr Radka SNAJDROVA
NOVARTIS PHARMA AG, Basel, Switzerland
Read more